Simply, how does the Moderna vaccine work? Is it different from the “Pfizer” vaccine?

Scientifically speaking, the two vaccines have a very similar mechanism of action, while both differ from the dominant patterns followed by the usual vaccines.

It was customary for the vaccine to consist mainly of weak or inactivated viruses or parts of the virus that do not cause disease to the body, but rather only inform it of the disease, and stimulate it to produce antibodies that remain in it. for life and defend against this virus in the future.

As for the “Moderna” vaccine, it takes a different approach, as it consists of small pieces of DNA “mRNA” that stimulate the body to produce the protein on the surface of the emerging corona virus.

It is this protein, which gives the Corona virus its distinctive form of coronavirus, which helps the microorganism attach itself to human cells in the early stages of the disease.

Once this foreign protein is produced in the body, the immune system senses the presence of the virus and begins to produce the antibody, as if the person is already sick.

This method is similar to how the recently announced Pfizer and Biontech vaccines work.

Both vaccines require two injections, spaced several weeks apart.

A major advantage of the Moderna vaccine is that it does not need to be stored in extremely cold temperatures like the Pfizer vaccine, which makes it easier to distribute.

Moderna expects the vaccine to be stable at normal coolant temperatures of 2-8 degrees Celsius for 30 days and can be stored for up to six months at minus 20 degrees Celsius.

In return, the Firees vaccine must be shipped and stored at minus 70 degrees Celsius, which is the normal temperature in winter in Antarctica. At normal coolant temperatures, it can be stored for up to five days.

And Moderna announced on Monday that its vaccine offered strong protection and provided a glimmer of hope in a grim situation following the high number of deaths from coronavirus infections in the United States and around the world.

The company said its vaccine appears to be 94.5% effective, according to preliminary data based on a study by the company that is still ongoing.

Moderna expects to receive around 20 million doses destined for the United States by the end of 2020, while Pfizer and its German partner expect to receive around 50 million doses worldwide by the end of the year.